SUBSCRIBE
SUBSCRIBE

Phase 2

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Chimerix, Inc.'s Brincidofovir Antiviral To Be Tested In West African Ebola Trial
November 14, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
AbbVie’s Hepatitis C Drug Cures 97 Percent In Phase 2 Transplant Patients Study
November 11, 2014
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Regeneron, Sanofi’s Dual-Action Biotech Asthma Drug Performs Well In Key Test
November 11, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Merck & Co.'s Four-Week Hep C Regimen With Gilead Sciences, Inc.'s Sovaldi Fails To Deliver
November 10, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Intercept Pharmaceuticals Tanks As Liver Drug Needs Safety Review: Investigators
November 7, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Merck & Co. Reports Positive Data From Phase 2b Doravirine Trial
November 3, 2014
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Receptos Soars As Bowel Disorder Drug Meets Phase 2 Goals
October 28, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Regulus Therapeutics, Inc. Gets Seat At Hepatitis C Table With Impressive Phase 1 Results
October 22, 2014
 · 
1 min read
Ebola Clinical Trials: Big Name Players In The Ebola Race
BioCapital
Ebola Clinical Trials: Big Name Players In The Ebola Race
October 20, 2014
 · 
12 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Cannabis Biopharma GW Pharmaceuticals Sees Disappointing Data For Colitis Drug
October 14, 2014
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren’s Syndrome in China
May 8, 2026
 · 
3 min read
Press Releases
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
May 8, 2026
 · 
12 min read
Press Releases
Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting
May 8, 2026
 · 
6 min read
Press Releases
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
May 8, 2026
 · 
8 min read
Press Releases
Ukko Announces First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment
May 7, 2026
 · 
3 min read
Press Releases
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 7, 2026
 · 
12 min read
Press Releases
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
May 7, 2026
 · 
8 min read
Press Releases
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
May 7, 2026
 · 
6 min read
Press Releases
Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
May 7, 2026
 · 
7 min read
Press Releases
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 7, 2026
 · 
5 min read
Press Releases
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 7, 2026
 · 
15 min read
Press Releases
PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients
May 7, 2026
 · 
5 min read
Press Releases
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
 · 
18 min read
Press Releases
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
May 7, 2026
 · 
7 min read
Press Releases
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 7, 2026
 · 
1 min read
Press Releases
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
May 6, 2026
 · 
5 min read
Press Releases
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 6, 2026
 · 
10 min read
Press Releases
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
 · 
14 min read
Press Releases
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
May 6, 2026
 · 
10 min read
Press Releases
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
May 6, 2026
 · 
12 min read
Load More